Raphael Levi

Title: Raphael Levi: Innovator in Peptide-based Vaccines

Introduction

Raphael Levi is a notable inventor based in Yahud, Israel. He has made significant contributions to the field of vaccine development, particularly focusing on peptide-based solutions for influenza. With a total of 3 patents to his name, Levi's work is paving the way for innovative approaches to combating viral infections.

Latest Patents

One of Levi's latest patents is a human synthetic peptide-based influenza vaccine designed for intranasal administration. This vaccine comprises a mixture of flagella containing at least four epitopes of the influenza virus that are reactive with human cells. Each epitope is expressed individually in flagellin. The influenza virus epitopes selected for this vaccine include: (i) one B-cell hemagglutinin (HA) epitope; (ii) one T-helper hemagglutinin (HA) or nucleoprotein (NP) epitope that can bind to many HLA molecules; and (iii) at least two cytotoxic lymphocyte (CTL) nucleoprotein (NP) or matrix protein (M) epitopes that are restricted to the most prevalent HLA molecules in different human populations.

Career Highlights

Levi is currently associated with Yeda Research and Development Co. Ltd., where he continues to innovate in the field of vaccine research. His work has garnered attention for its potential to enhance the effectiveness of influenza vaccines.

Collaborations

Throughout his career, Levi has collaborated with esteemed colleagues such as Ruth Arnon and Tamar Ben-Yedidia. These partnerships have contributed to the advancement of his research and the development of groundbreaking vaccine technologies.

Conclusion

Raphael Levi's contributions to peptide-based vaccines represent a significant advancement in the fight against influenza. His innovative approach and dedication to research continue to inspire progress in the field of immunology.